Sun Pharmaceutical Industries has acquired 100% of shares of Libra Merger, a company incorporated in Israel. The objective of acquisition is to facilitate consolidation of business in Israel. Earlier, the company’s specialty product Ilumetri had been included in category B of China's national reimbursement drug list. Ilumetri is indicated for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Sun Pharmaceutical Industries is among the largest specialty generic pharmaceutical company and India's top pharmaceutical company.
